We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Filtration Method Developed for Cord Blood

By LabMedica International staff writers
Posted on 27 Dec 2012
A novel filtration system using a nonchemical-coated and nonwoven polyester fabric filter, which traps cells through affinity, has been developed for cord blood. More...


Cord blood (CB) is being increasingly used as a source of hematopoietic stem cells for transplantation to treat diseases of the blood and immune systems, and there is an urgent need to expand CB banking worldwide.

Scientists at Kyushu University School of Medical Science (Fukuoka, Japan) developed a polyester fabric filter specifically for CB, which traps cells and does not require centrifugation or potentially toxic chemicals. Normally CB processing requires costly machinery or a clean room that hampers wider application of cord blood transplantation (CBT) particularly in the developing countries.

The collection efficacy was calculated by counting total nucleated cells (TNCs) using an automated hematology analyzer KX-21 (Sysmex; Kobe, Japan) or ABX Pentra hematology analyzer (Horiba; Kyoto, Japan). The red blood cell (RBC) compartment combines the RBCs and the nucleated red cells. The number of mononuclear cells (MNCs) or polymorphonuclear cells (PMNs) was calculated as the product of TNC count, and the percentage of each population analyzed by FACSCanto flow cytometry (BD Biosciences; San Jose, CA, USA). Collection efficacy was defined as the ratio of cell number in the collected fraction relative to the introduced cord blood.

The loss of TNCs, MNCs, and PMNs was less than 5%. The loss of CD34+ cells was only 0.5%, indicating the minimal loss of nucleated cells and CD34+ cells during this process. On the other hand, 84.8% of RBCs and 61.0% of platelets were in the flow-through fraction. These data indicated that the device could trap nucleated cells and remove RBCs and platelets efficiently. Therefore cell processing with the device resulted in minimum cell loss of total cells and CD34+ cells, without impairing the ability of CD34+ cells to engraft and differentiate both in vivo and in vitro.

The authors concluded that CB processing with the device is simple, cost-effective, and nontoxic without requiring costly equipment will facilitate international CB banking. This will help in meeting the increasing worldwide demand for CB for allogeneic hematopoietic stem cell transplantation. The study was published on December 14, 2012, in the International Journal of Laboratory Hematology.

Related Links:
Kyushu University School of Medical Science
Sysmex
Horiba



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.